In NSCLC, ICIs targeting the programmed cell death protein 1 (PD‐1) / programmed death ligand 1 (PD‐L1) pathway, such as PD‐1 inhibitors (nivolumab and pembrolizumab) and PD‐L1 inhibitors (atezolizumab), have significantly prolonged the overall survival (OS) and progression‐free survival (PFS) compared with those of conventional anticancer drugs.19, 20, 21, 22. The gene discussed is CD274; the disease is non-small cell lung carcinoma.